Abstract
The expansion of a leukemia clone bearing a Bcr-Abl kinase domain mutation is associated with acquired resistance to imatinib and may also predict disease progression in patients with Philadelphia-positive chronic myeloid leukemia (CML). Here we report results of pyrosequencing to quantitate the non-mutated and mutant alleles in 12 CML patients monitored over periods ranging from 11 to 58 months, and describe three contrasting kinetic patterns: Group 1 – in four patients total BCR-ABL transcript numbers remained high with the mutant allele predominating; Group 2 – in four patients the total number of BCR-ABL transcripts fell to low levels but the mutant allele predominated; and Group 3 – in four other patients the total level of transcripts remained high (n=2) or fell (n=2) but the mutant clone persisted at relatively low level. In Group 2 the mutant leukemia clone was presumably still relatively sensitive to imatinib but in Group 1 the leukemia could be classified as resistant. In Group 3 patients the imatinib sensitivity of the leukemia was variable. We conclude that a mutant clone does not necessarily have a proliferative advantage and its presence does not always account for resistance to imatinib. Other mechanisms underlie resistance in at least some patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.
Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432.
Deininger M, Buchdunger E, Druker BJ . The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640–2653.
Druker BJ, Lydon NB . Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105: 3–7.
Marin D, Kaeda J, Szydlo R, Saunders S, Fleming A, Howard J et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia 2005; 19: 509–512.
Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J . Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 2000; 289: 1938–1942.
Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880.
Shah N, Nicoll J, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–223.
Azam M, Latek RR, Daley GQ . Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112: 831–843.
Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276–283.
Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A et al. Abl mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with greater likelihood of progression to blast crisis and shorter survival: a study of the GIMEMA Working Party on chronic myeloid leukemia. J Clin Oncol 2005; 23: 4100–4109.
Cross NC, Lin F, Chase A, Bungey J, Hughes TP, Goldman JM et al. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929–1936.
Kaeda J, Chase A, Goldman JM . Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia. Acta Haematol 2002; 107: 64–75.
Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgard N et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease in leukemia – A Europe Against Cancer Program. Leukemia 2003; 17: 2318–2357.
Ramon D, Braden M, Adams S, Marincola FM, Wang L . Pyrosequencing trade mark: a one-step method for high resolution HLA typing. J Transl Med 2003; 1: 9.
Ronaghi M, Uhlen M, Nyren P . A sequencing method based on real-time pyrophosphate. Science 1998; 281: 363–365.
Hochberg EP, Miklos DB, Neuberg D, Eichner DA, McLaughlin SF, Mattes-Ritz A et al. A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplant. Blood 2003; 101: 363–369.
Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW . Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003; 101: 4611–4614.
La Rosee P, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ . Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res 2002; 62: 7149–7153.
von Bubnoff N, Schneller F, Peschel C, Duyster J . BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359: 487–491.
Goldman JM, Melo JV . Chronic myeloid leukemia – advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451–1464.
Willis S, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D et al. High sensitivity of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106: 2128–2137.
Hochhaus A, La Rosee P . Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321–1331.
Schindler T, Bornmann W, Pellicena P, Pellicena P, Miller WT, Clarkson B et al. Structural mechanism of STI-571 inhibition of Abelson tyrosine kinase. Science 2000; 289: 1938–1942.
Corbin AS, Buchdunger E, Pascal F, Druker BJ . Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem 2002; 277: 32214–32219.
Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100: 1014–1018.
Kreuzer KA, le Coutre P, Landt O, Na IK, Schwarz M, Schultheis K et al. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann Hematol 2003; 82: 284–289.
Roumiantsev S, Shah SP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL . Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 2002; 99: 107000–110705.
Barnes DJ, Palaiologou D, Panousopoulou E, Schultheis BS, Wong ASM, Wong A et al. BCR-ABL expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Res 2005; 65: 8912–8919.
Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003; 101: 2368–2373.
Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690–698.
Acknowledgements
We are grateful to Dr Brian J Druker (Oregon Health and Science University, Portland, OR, USA) for donation of the BaF3/BCR-ABL-transfected cell lines. We thank Catharina Andreasson for invaluable assistance with data management. The pyrosequencing instrument was made available to us by Dr John McVey. This work was supported in part by grants from the Leukaemia Research Grant (UK) and the UK charity Leuka.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Khorashad, J., Anand, M., Marin, D. et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia 20, 658–663 (2006). https://doi.org/10.1038/sj.leu.2404137
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404137
Keywords
This article is cited by
-
BCR-ABL triggers a glucose-dependent survival program during leukemogenesis through the suppression of TXNIP
Cell Death & Disease (2023)
-
Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies
Current Hematologic Malignancy Reports (2022)
-
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
Scientific Reports (2022)
-
Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia
Molecular Diagnosis & Therapy (2017)
-
Drug repositioning for personalized medicine
Genome Medicine (2012)